References
- Sponer G, Strein K, Muller-Beckmann B, Bartsch W. Studies on the mode of vasodilating action of carvedilol. J Cardiovasc Pharmacol 1987;10:S42–48
- Sponer G, Bartsch W, Strein K, et al. Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987;9:317–27
- Sponer G, Bartsch W, Hooper RG. Drugs acting as multiple receptors: β-blockers with additional properties. In: Ganten D, Mulrow PJ, eds. Pharmacology of antihypertensive therapeutics. Handbook of pharmacology. Vol. 93. Berlin Heidelberg New York: Springer; 1990:132–226
- Ruffolo RR Jr, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38:S82–88
- van der Does R, Eberhardt R, Derr I, et al. Treatment of chronic stable angina with carvedilol in comparison with nifedipine s.r. Eur Heart J 1991;12:60–4
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55
- Oldham HG, Clarke SE. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(−)-carvedilol. Drug Metab Dispos 1997;25:970–7
- Bart J, Dijkers EC, Wegman TD, et al. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol 2005;145:1045–51
- Hamberg P, Woo MM, Chen LC, et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 2011;68:805–13
- Kummer O, Hammann F, Moser C, et al. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2011;67:63–71
- Spriet I, Grootaert V, Meyfroidt G, et al. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction. Eur J Clin Pharmacol 2013;69:737–8
- Hussaini T, Ruping MJ, Farowski F, et al. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011;31:214–25
- Yasuda K, Lan LB, Sanglard D, et al. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002;303:323–32
- Lin G, Wang C, Qiu X, et al. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Drug Dev Ind Pharm 2014;40:1616–22
- Bachmakov I, Werner U, Endress B, et al. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol 2006;20:273–82
- De Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 1990;29:486–90
- Nikolic VN, Jankovic SM, Velickovic-Radovanovic R, et al. Population pharmacokinetics of carvedilol in patients with congestive heart failure. J Pharm Sci 2013;102:2851–8
- Zarghi A, Foroutan SM, Shafaati A, Khoddam A. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J Pharm Biomed Anal 2007;44:250–3
- Hokama N, Hobara N, Kameya H, et al. Rapid and simple micro-determination of carvedilol in rat plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;732:233–8
- Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335–46
- Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 2011;12:861–72
- Zhang S, Pillai VC, Mada SR, et al. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 2012;42:409–16